Fortune India has published list of 500 mid-size companies who ranked them on various parameters based on the results of 2013-2014. Ajanta pharma features very prominently in the lists. Ajanta’s ranking on various pararmeters is given below:
Ranked 3’d largest Wealth Creator on 5 year CAGR 93.14%
Ranked 10th on Capital Employed (ROCE)
Ranked 21st in Net profit .
Ranked 182nd in Sales
On 17’th August 2015, Fortune India organized an award function to present the awards to Top 10 largest weatth creator companies and Ajanta is one of those elite companies.
The awards were presented by Mr. Piyush Goyal, Minister of State-Power,Coal& New and Renewable Energy, Govt. of India to Mr. yogesh Agrawal, Managing Director and Mr.Rajesh Agrawal,Jt.Managing Director of the company.
Ajanta Pharma, “One of the Giants of Tomorrow” – Fortune India
We are pleased to share with you that Ajanta Pharma has been honoured as “ONE OF THE GIANTS OF TOMORROW” by prestigious Fortune India magazine on 19th August 2016 at New Delhi.
The honour was conferred to our Managing Director, Mr. Yogesh Agrawal and our Jt. Managing Director, Mr. Rajesh Agrawal at the hands of Hon. Mr. Nitin Gadkari, Union Minister for Road Transport and Highways and Shipping, Govt of India. This is the 2nd year in row where Ajanta has received the recognition from Fortune India.
Fortune India (June 2016 Issue) published the list of mid-size companies based on the financial year 2014-15 results and we are pleased to share with you that Ajanta has been ranked 3rd Top Wealth creator over last 5 years.
Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA. In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. Its brands in each of sub-therapeutic areas or molecules hold leadership positions. In Emerging Markets, company has presences in Africa, Asia, Middle East, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc. In USA, company has already no. of approved ANDA’s which are either commercialized or in process of being commercialized and large no. of ANDA’s are awaiting US FDA approval. We have state-of-the-art research facilities for formulation (finished product) and API development located at Mumbai, India. Our R&D capabilities are evident from number of products launched 1st to market by the company providing patients most needed compliance and convenience. A dedicated and focused team of more than 750 Ajantaites work for R&D, which is growing continuously. Ajanta has four formulations manufacturing facilities located in India and 1 in Mauritius. Besides that, we also have an API manufacturing facility located at Waluj, India. Ajanta’s flagship formulation facility at Paithan (Maharashtra, India) has approval of USFDA, WHO- Geneva (prequalification), UNICEF and many regulatory authorities from different parts of the world. We continuously invest in enhancing our existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet the company’s growth requirements. We are in process of setting up 1 more formulations manufacturing facility for domestic and emerging markets at Guwahati, Assam. Please visit http://ajantapharma.com/ for more information. Contact: email@example.com
Speciality Branded Generics, Generics, Complex Formulations
98 Ajanta House Charkop, Kandivili West Mumbai,Maharashtra 400067 India
Rajesh Agrawal (left), Ajanta Pharma’s joint managing director, with brother Yogesh, who is also managing director of the company, at their Kandivli facility
Ajanta Pharma needed a shot of its own medicine, an energiser like 30-Plus. It found its antidote in the new generation of Agrawals: Mannalal’s sons, Yogesh and Rajesh.
“When I joined Ajanta (in 2000), and realised what was going on, I wanted to run away. I thought to myself, ‘Why did I return from the US? I could have had a job there,’” says Rajesh, 39, Ajanta’s joint managing director, who has a management degree from Bentley College, Massachusetts. “It was tough in the beginning, especially the situation with creditors and debtors.”
Together, Rajesh and his older brother Yogesh, 43, who is managing director, changed Ajanta’s trajectory by focusing on the ‘specialty’ generic drug market and putting an end to the company’s legacy businesses, which included OTC drug sales and supplying drugs to government health agencies in India and other countries.
This was a risky move, but it has paid off. Ajanta Pharma closed FY15 with a consolidated net sales of Rs 1,481 crore and a net profit of Rs 310 crore (this is a compound annual growth rate, or CAGR, of 57 percent for four years since 2011). In terms of net sales, it recorded a CAGR of 31 percent for the same period. This growth has come on a low base, but the signs are encouraging. Its market value currently stands at around Rs 13,500 crore; this is a 65-fold growth in 15 years.
/////////Ajanta Pharma, “One of the Giants of Tomorrow” , Fortune India, AWARD, Fortune India, RAJESH AGRAWAL